Eric Raymond
Department of Medicine
Institute Gustave-Roussy
Villejuif
France
Name/email consistency: high
- Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastoma. Raymond, E., Fabbro, M., Boige, V., Rixe, O., Frenay, M., Vassal, G., Faivre, S., Sicard, E., Germa, C., Rodier, J.M., Vernillet, L., Armand, J.P. Ann. Oncol. (2003)
- Multicentre phase II and pharmacokinetic study of RFS2000 (9-nitro-camptothecin) administered orally 5 days a week in patients with glioblastoma multiforme. Raymond, E., Campone, M., Stupp, R., Menten, J., Chollet, P., Lesimple, T., Fety-Deporte, R., Lacombe, D., Paoletti, X., Fumoleau, P. Eur. J. Cancer (2002)
- Pemetrexed disodium combined with oxaliplatin, SN38, or 5-fluorouracil, based on the quantitation of drug interactions in human HT29 colon cancer cells. Raymond, E., Louvet, C., Tournigand, C., Coudray, A.M., Faivre, S., De Gramont, A., Gespach, C. Int. J. Oncol. (2002)
- Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a one-hour infusion every three weeks in patients with advanced cancer. Raymond, E., ten Bokkel Huinink, W.W., Taïeb, J., Beijnen, J.H., Faivre, S., Wanders, J., Ravic, M., Fumoleau, P., Armand, J.P., Schellens, J.H. J. Clin. Oncol. (2002)
- Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction. Raymond, E., Boige, V., Faivre, S., Sanderink, G.J., Rixe, O., Vernillet, L., Jacques, C., Gatineau, M., Ducreux, M., Armand, J.P. J. Clin. Oncol. (2002)
- Cellular and molecular pharmacology of oxaliplatin. Raymond, E., Faivre, S., Chaney, S., Woynarowski, J., Cvitkovic, E. Mol. Cancer Ther. (2002)
- Effects of hydroxyurea on extrachromosomal DNA in patients with advanced ovarian carcinomas. Raymond, E., Faivre, S., Weiss, G., McGill, J., Davidson, K., Izbicka, E., Kuhn, J.G., Allred, C., Clark, G.M., Von Hoff, D.D. Clin. Cancer Res. (2001)
- DNA G-quadruplexes, telomere-specific proteins and telomere-associated enzymes as potential targets for new anticancer drugs. Raymond, E., Soria, J.C., Izbicka, E., Boussin, F., Hurley, L., Von Hoff, D.D. Invest. New. Drugs (2000)
- Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Raymond, E., Faivre, S., Armand, J.P. Drugs (2000)